Exclusive: STAT has learned that Eli Lilly and the FDA allowed a 79-year-old to gain extraordinary access to an experimental obesity drug through the agency’s “compassionate use” program.
Eli Lilly granted a 79-year-old patient extraordinary access to an experimental obesity drug. This was facilitated through the FDA's
Market Samachar is a news aggregator. This article was originally published by STAT. Tap the button above to read the full story on their site.